Drugs / EVM14
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07614646 | Nov 2026 → Jul 2028 expected | non-small cell squamous lung carcinoma | Everest Medicines (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07095868 | Nov 2025 → Nov 2029 expected | — | Everest Medicines (Beijing) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVM14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07095868 ↗ |
| Modality | Vaccine | “Cancer Vaccine” NCT07614646 ↗ |
| Route | Intramuscular | “EVM14 administered intramuscularly (IM)” NCT07095868 ↗ |